VenBio related stories
All articles and analysis
Irish biotech firm Heart Metabolics snags $20 mln Series A fundsHeart Metabolics said Thursday that it has closed $20 million in Series A funding. The investors were venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. Based in Dublin, Ireland, Heart Metabolics is a biotech firm focused on developing treatments for cardio-metabolic diseases.
First quarter VC roundup - Clio’s $20 mln Series C caps solid start to the yearThe $20 million Series C financing of Clio capped a solid start to Canadian venture capital deal-making in 2014. In an interview with peHUB Canada, the startup's co-founder and CEO Jack Newton explains why the Vancouver-based provider of cloud-based tools to the legal industry is gaining traction in the marketplace. At the same time, Canadian life sciences companies have taken an especially large share of venture cash since January, suggesting that investment activity in the sector may be staging a comeback after a quiet 2013.
- First quarter VC roundup - Clio’s $20 mln Series C caps solid start to the year
The $20 million Series C financing of Clio capped a solid start to Canadian venture capital deal-making in 2014. In an interview with peHUB Canada, the startup's co-founder and CEO Jack Newton explains why the Vancouver-based provider of cloud-based tools to the legal industry is gaining traction in the marketplace. At the same time, Canadian life sciences companies have taken an especially large share of venture cash since January, suggesting that investment activity in the sector may be staging a comeback after a quiet 2013.
Top VC deals done in Canada in first quarterCanada’s Venture Capital and Private Equity Association and research partner Thomson Reuters will in May publish their full report on Canadian venture capital deal-making in the first quarter of 2014. In the meantime, peHUB Canada has compiled an early list of some of the top disclosed financings completed since January.
- Top VC deals done in Canada in first quarter
Canada’s Venture Capital and Private Equity Association and research partner Thomson Reuters will in May publish their full report on Canadian venture capital deal-making in the first quarter of 2014. In the meantime, peHUB Canada has compiled an early list of some of the top disclosed financings completed since January.
Aurinia nets $52 mln to develop treatment for lupus nephritisAurinia Pharmaceuticals Inc (TSX-V: AUP) has completed a US$52 million private placement. The deal was led by venBio, New Enterprise Associates, Redmile Group, RA Capital Management, Great Point Partners and Apple Tree Partners, with the participation of existing investors Lumira Capital, ILJIN Life Science and Difference Capital. Lumira, Difference Capital and ILJIN in 2013 helped finance Aurinia's merger /canada/2013/09/24/isotechnika-aurinia-merger-completed-6-mln-investment/ with Isotechnika Pharma Inc. The Edmonton-based company intends to use the new funds for the clinical and non-clinical development of its lead drug candidate, a therapy for treating lupus nephritis. Aurinia's current leadership team includes former senior managers of Aspreva Pharmaceuticals Corp, which was acquired in 2008.
Stem Cell Therapeutics raises $33 mln to advance cancer stem cell discoveriesStem Cell Therapeutics Corp (TSX-V: SSS), a Toronto-based immuno-oncology company developing cancer stem cell-related therapeutics, has obtained $33 million in private placement funding. The transaction was led by an unidentified U.S. healthcare fund, with participation from Special Situations Funds, Ridgeback Capital, Merlin Nexus, Sabby Capital, venBio, Opaleye Management and HSMR Advisors. Investment proceeds will be used to advance the company's CD47 cancer stem cell program through IND-enabling studies, manufacturing and phase 1 clinical trials. Stem Cell Therapeutics in Apr. 2013 acquired Trillium Therapeutics Inc, a Toronto-based biopharmaceuticals company that had been venture-backed since 1997.
- Solstice Biologics Closes on $18M
Solstice Biologics, a biotech startup focused on the problem of targeting and delivering nucleic acid therapeutics, has raised $18 million in Series A financing led by venBio and joined by Aeris Capital AG. The company also announced that it has acquired an exclusive license to certain University of California, San Diego intellectual property.
- Labrys Biologics Seals $31M Series A
Labrys Biologics, a company developing treatments for chronic migraines, has raised a $31 million Series A financing. VenBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures all participated in the round. The money helps Labrys acquire the worldwide rights to the RN-307 antibody from Pfizer Inc.
- Aragon Pharmaceuticals Nabs $50M
Aragon Pharmaceuticals has closed a $50 million Series D round, the company announced Thursday. Aragon is developing therapeutics for hormone-driven cancers. venBio led the financing with participation from existing investors Topspin Fund, Aisling Capital, OrbiMed Advisors and The Column Group.